These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
366 related items for PubMed ID: 10206756
21. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. Espinel-Ingroff A. J Clin Microbiol; 1998 Jan; 36(1):198-202. PubMed ID: 9431946 [Abstract] [Full Text] [Related]
22. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. Oakley KL, Moore CB, Denning DW. J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534 [Abstract] [Full Text] [Related]
23. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Fothergill AW, Rinaldi MG, Sutton DA. Med Mycol; 2009 Feb; 47(1):41-3. PubMed ID: 19107637 [Abstract] [Full Text] [Related]
24. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin. Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN. Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656 [Abstract] [Full Text] [Related]
29. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Radford SA, Johnson EM, Warnock DW. Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501 [Abstract] [Full Text] [Related]
32. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals. Arredondo-García JL, Amábile-Cuevas CF, RedMic2 Study Group. J Infect Dev Ctries; 2009 Jun 01; 3(5):398-401. PubMed ID: 19759511 [Abstract] [Full Text] [Related]
33. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Bueno JG, Martinez C, Zapata B, Sanclemente G, Gallego M, Mesa AC. Clin Exp Dermatol; 2010 Aug 01; 35(6):658-63. PubMed ID: 19874354 [Abstract] [Full Text] [Related]
35. In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae. Kachuei R, Khodavaisy S, Rezaie S, Sharifynia S. J Mycol Med; 2016 Mar 01; 26(1):17-21. PubMed ID: 26852191 [Abstract] [Full Text] [Related]
36. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp. Maesaki S, Iwakawa J, Higashiyama Y, Miyazaki Y, Yanagihara K, Tomono K, Tashiro T, Kohno S. J Infect Chemother; 2000 Jun 01; 6(2):101-3. PubMed ID: 11810544 [Abstract] [Full Text] [Related]
38. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Lewis RE, Wiederhold NP, Klepser ME. Antimicrob Agents Chemother; 2005 Mar 01; 49(3):945-51. PubMed ID: 15728887 [Abstract] [Full Text] [Related]